Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications



Marra, Fiona ORCID: 0000-0003-1326-1149, zu Siederdissen, Christoph Hoener, Khoo, Saye, Back, David, Schlag, Michael, Ouwerkerk-Mahadevan, Sivi, Bicer, Ceyhun, Lonjon-Domanec, Isabelle, Jessner, Wolfgang, Beumont-Mauviel, Maria
et al (show 2 more authors) (2018) Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 84 (5). 961 - 971.

[img] Text
Marra et al. DDIs SMV BJCP Jan 2018.docx - Accepted Version

Download (402kB)
Item Type: Article
Uncontrolled Keywords: DDI, drug-drug interaction, HCV, hepatitis C virus, simeprevir, SMV
Depositing User: Symplectic Admin
Date Deposited: 07 Jun 2018 11:40
Last Modified: 18 Jan 2021 21:11
DOI: 10.1111/bcp.13519
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3022210